GT Biopharma, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
GT Biopharma filed an 8-K on August 14, 2026 reporting submission of matters to a vote of security holders (Item 5.07) and financial statements/exhibits (Item 9.01). The filing contains no disclosed dollar amounts, transaction details, counterparties, share counts, or specific outcomes of any shareholder vote. The actual voting results and matters voted upon are not detailed in the accessible filing metadata.
Why this rating
Routine shareholder vote disclosure with no material terms disclosed. No business impact quantifiable from filing text.
Extracted items
- 5.07 shareholder vote
- 9.01 exhibits
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.